Droia Ventures operates less like a typical capital provider and more like a company-building platform, running its own scientific arm, Droia Labs, to validate ideas for early drug-development companies, while staying narrowly focused on oncology and genetic disease through separate funds for each area. Its team includes veteran biotech operators—such as a former architect of major industry deals and founders of past rare-disease companies—who stress patient-experience insight in their investment decisions and favor building strong, opinionated leadership teams early rather than waiting until it's financially comfortable.